Literature DB >> 11309784

Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization.

F Tsukamoto1, Y Miyoshi, C Egawa, T Kasugai, S Takami, J Inazawa, S Noguchi.   

Abstract

BACKGROUND: The clinicopathologic characteristics of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization (FISH) have yet to be clarified.
METHODS: Fine-needle aspiration biopsy (FNAB) samples were obtained from 113 breast tumors and were subjected to FISH analysis using centromeric probes for chromosomes 1, 11, and 17 to study a numerical aberration of these chromosomes and its correlation with various clinicopathologic features of breast tumors.
RESULTS: Polysomy was observed in 77.0%, 50.5%, and 37.2% of breast carcinoma samples for chromosomes 1, 11, and 17, respectively, and monosomy was observed in 1.8%, 8.8%, and 22.1% for chromosomes 1, 11, and 17, respectively. High histologic grade showed a significant correlation (P < 0.05) with polysomy of chromosome 11. Lymph node metastasis showed a significant correlation (P < 0.05) with polysomy of all three chromosomes, and positivity of lymph node metastasis increased as the number of polysomic chromosomes increased. In addition, estrogen receptor negativity was correlated significantly (P < 0.05) with monosomy of chromosome 17, and progesterone receptor negativity was correlated significantly (P < 0.05) with polysomy of chromosomes 11 and 17.
CONCLUSIONS: Aneusomy of chromosome 1, 11, or 17 detected by FISH is correlated significantly with various clinicopathologic features of breast carcinoma. Because FISH analysis of chromosomal aneusomy can be done using FNAB samples, this technique seems to have the potential to be used for a better, preoperative definition of the biologic characteristics of breast tumors.

Entities:  

Mesh:

Year:  2001        PMID: 11309784     DOI: 10.1002/cncr.9024

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.

Authors:  Anna Zaczek; Aleksandra Markiewicz; Anna Supernat; Natalia Bednarz-Knoll; Burkhardt Brandt; Barbara Seroczyńska; Jarosław Skokowski; Jolanta Szade; Piotr Czapiewski; Wojciech Biernat; Marzena Wełnicka-Jaśkiewicz; Jacek Jassem
Journal:  Pathol Oncol Res       Date:  2012-03-18       Impact factor: 3.201

2.  Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.

Authors:  Birgitta Schlüter; Roswitha Gerhards; Dirk Strumberg; Rudolf Voigtmann
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-09       Impact factor: 4.553

3.  Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification.

Authors:  Matteo Brunelli; Alessia Nottegar; Giuseppe Bogina; Anna Caliò; Luca Cima; Albino Eccher; Caterina Vicentini; Lisa Marcolini; Aldo Scarpa; Serena Pedron; Eleonora Brunello; Sakari Knuutila; Anna Sapino; Caterina Marchiò; Emilio Bria; Annamaria Molino; Luisa Carbognin; Giampaolo Tortora; Bharat Jasani; Keith Miller; Ibrahim Merdol; Lucia Zanatta; Licia Laurino; Tiina Wirtanen; Giuseppe Zamboni; Marcella Marconi; Marco Chilosi; Erminia Manfrin; Guido Martignoni; Franco Bonetti
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

4.  Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.

Authors:  Priti Lal; Paulo A Salazar; Marc Ladanyi; Beiyun Chen
Journal:  J Mol Diagn       Date:  2003-08       Impact factor: 5.568

Review 5.  Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.

Authors:  Monica M Reinholz; Amy K Bruzek; Daniel W Visscher; Wilma L Lingle; Matthew J Schroeder; Edith A Perez; Robert B Jenkins
Journal:  Lancet Oncol       Date:  2009-03       Impact factor: 41.316

6.  Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.

Authors:  Marta Salido; Ignasi Tusquets; Josep M Corominas; Marta Suarez; Blanca Espinet; Cristina Corzo; Meritxell Bellet; Xavier Fabregat; Sergi Serrano; Francesc Solé
Journal:  Breast Cancer Res       Date:  2005-01-26       Impact factor: 6.466

7.  HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.

Authors:  Sasagu Kurozumi; Mary Padilla; Masafumi Kurosumi; Hiroshi Matsumoto; Kenichi Inoue; Jun Horiguchi; Izumi Takeyoshi; Tetsunari Oyama; Jim Ranger-Moore; D Craig Allred; Eslie Dennis; Hiroaki Nitta
Journal:  Breast Cancer Res Treat       Date:  2016-06-18       Impact factor: 4.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.